Healthcare Services

Global Neurotrophic Keratitis Treatment Industry Trends and Market Growth Forecast for 2026–2030

April 3, 2026April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Neurotrophic Keratitis Treatment Market Over The 2026–2030 Period?

The neurotrophic keratitis treatment market has experienced rapid expansion over recent years. It is projected to grow from $1.47 billion in 2025 to $1.99 billion in 2026, at a compound annual growth rate (CAGR) of 36.1%. This historical growth can be attributed to factors such as the increasing prevalence of diabetes-related corneal disorders, a rising incidence of herpes simplex eye infections, the growth in ophthalmology specialty clinics, improved awareness of neurotrophic keratitis among clinicians, and the expansion of hospital-based eye care services.

The neurotrophic keratitis treatment market is anticipated to show significant expansion over the coming years. It is projected to reach $6.78 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 35.8%. This growth during the forecast period is primarily driven by breakthroughs in regenerative ophthalmic therapies, an increase in approvals for rhNGF-based drugs, an expanding aging population susceptible to nerve degeneration, rising investments in research for rare eye diseases, and enhanced access to advanced eye care in emerging markets. Key trends expected in this period include the wider acceptance of recombinant human nerve growth factor therapies, a growing preference for less invasive corneal repair procedures, a greater emphasis on early diagnosis and intervention, the proliferation of homecare-based ophthalmic treatment solutions, and ongoing advancements in amniotic membrane preservation techniques.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12968&type=smp

What Drivers Are Expected To Influence The Neurotrophic Keratitis Treatment Market During The Forecast Period?

The increasing occurrence of eye diseases is expected to propel the expansion of the neurotrophic keratitis treatment market moving forward. These conditions encompass a wide array of ailments affecting the structure and function of the eyes, often leading to impaired vision or blindness. The surge in eye disease prevalence is driven by factors such as an aging population, lifestyle changes, and the rising incidence of chronic conditions like diabetes. Neurotrophic keratitis treatment supports ocular health by enhancing corneal sensation, promoting healing, preventing infection, and alleviating discomfort. For instance, in August 2023, according to the World Health Organization (WHO), a United Nations agency based in Switzerland, global estimates indicate that 2.2 billion people experience near or distance vision impairment, with 1 billion of these cases being preventable or untreated. Refractive errors and cataracts remain the primary global causes of vision loss, yet only 36% of individuals with refractive-error–related distance impairment and just 17% of those with cataract-related impairment have received appropriate care. Therefore, the growing prevalence of eye diseases is driving the growth of the neurotrophic keratitis treatment market.

How Is The Neurotrophic Keratitis Treatment Market Segmented Across Key Categories?

The neurotrophic keratitis treatment market covered in this report is segmented –

1) By Treatment: Topical Antibiotics, Recombinant Human Nerve Growth Factor (rhNGF), Amniotic Membrane Transplantation, Keratoplasty, Other Treatments

2) By Route Of Administration: Oral, Topical, Other Routes Of Administrations

3) By Application: Stage I, Stage II, Stage III

4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Topical Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics

2) By Recombinant Human Nerve Growth Factor (rhNGF): Cenegermin Ophthalmic Solution

3) By Amniotic Membrane Transplantation: Cryopreserved Amniotic Membrane, Dehydrated Amniotic Membrane

4) By Keratoplasty: Penetrating Keratoplasty, Lamellar Keratoplasty

5) By Other Treatments: Tarsorrhaphy, Therapeutic Contact Lenses

What Key Developments And Trends Are Impacting The Neurotrophic Keratitis Treatment Market?

Leading companies in the neurotrophic keratitis market are concentrating on developing advanced gene-therapy solutions, such as redosable eye-drop therapies, to enhance corneal healing, sustain nerve growth factor (NGF) expression, and alleviate patient treatment burden. Redosable eye-drop gene therapy describes a therapeutic method that delivers genes coding for NGF directly to the cornea, thereby enabling prolonged NGF production and supporting nerve regeneration over time. For instance, in July 2025, Krystal Biotech, a US-based biotechnology company, announced the dosing of the first patient in its Phase 1/2 EMERALD 1 study, which is a randomized, double-masked, placebo-controlled trial involving up to 27 adults with stage 2 or 3 neurotrophic keratitis. KB801, designed for twice-weekly administration over eight weeks, aims to safely encourage corneal healing while considerably reducing the treatment burden compared to the current six-times-a-day recombinant NGF eye drops.

Who Are The Dominant Players Shaping The Neurotrophic Keratitis Treatment Market Landscape?

Major companies operating in the neurotrophic keratitis treatment market are Eyevance Pharmaceuticals LLC, Johnson & Johnson, Allergan Inc, Alcon Inc, Bausch Health Companies Inc, Bausch & Lomb Inc, CooperVision Inc, Santen Pharmaceutical Co Ltd, Dompe farmaceutici S.p.A, Aurolab, Ocular Therapeutix Inc, Laboratoires Thea SAS, ReGenTree LLC, Contacare Ophthalmic Private Limited, Neuroptika Inc, Surgitech Innovation Private Limited, Aerie Pharmaceuticals Inc, RegeneRx Biopharmaceuticals Inc, Noveome Biotherapeutics Inc, Oyster Point Pharma, Claris Biotherapeutics, Recordati Rare Diseases, Mitotech SA, Kala Pharmaceuticals, Oxurion NV

Read the full neurotrophic keratitis treatment market report here:

https://www.thebusinessresearchcompany.com/report/neurotrophic-keratitis-treatment-global-market-report

Which Region Is Forecast To Lead The Neurotrophic Keratitis Treatment Market In Terms Of Market Size?

North America was the largest region in the neurotrophic keratitis treatment market in 2025. The regions covered in the neurotrophic keratitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neurotrophic Keratitis Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12968&type=smp

Browse Through More Reports Similar to the Global Neurotrophic Keratitis Treatment Market 2026, By The Business Research Company

Neuroscience Global Market Report

https://www.thebusinessresearchcompany.com/report/neuroscience-global-market-report

Neuroprosthetics Global Market Report

https://www.thebusinessresearchcompany.com/report/neuroprosthetics-global-market-report

Neuromodulation Global Market Report

https://www.thebusinessresearchcompany.com/report/neuromodulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795